Your browser does not allow JavaScript!
JavaScript is necessary for the proper functioning of this website. Please enable JavaScript or use a modern browser.
Open Science Slovenia
Open Science
DiKUL
slv
|
eng
Search
Browse
New in RUL
About RUL
In numbers
Help
Sign in
Novel strategies in systemic and local administration of therapeutic monoclonal antibodies
ID
Prašnikar, Monika
(
Author
),
ID
Bjelošević Žiberna, Maja
(
Author
),
ID
Gosenca Matjaž, Mirjam
(
Author
),
ID
Ahlin Grabnar, Pegi
(
Author
)
PDF - Presentation file,
Download
(993,65 KB)
MD5: 29664A6A4DF2ECC193CAD38A6BF4D403
URL - Source URL, Visit
https://www.sciencedirect.com/science/article/pii/S0378517324011116
Image galllery
Abstract
Monoclonal antibodies (mAbs) are an evolving class of biopharmaceuticals, with advancements evident across various stages of their development. While discovery, mAb chemical optimization, production and purification processes have been thoroughly reviewed, this paper aims to offer a summary of novel strategies in administration of mAbs. At present, systemic delivery of mAbs is available through parenteral administration routes with focus on subcutaneous administration. In addition, oriented toward patient-friendly therapy, other less invasive administration routes of mAbs, such as inhalation, nasal, transdermal, and oral administration, are explored. Literature data reveals the potential for local delivery of mAbs via inhalation, nasal, transdermal, intratumoral, intravitreal and vaginal administration, offering high efficacy with fewer systemic adverse effects. However, to date, only mAb medicines are available for intravitreal administration, mainly due to higher bioavailability, and an intranasal spray is authorised as a medical device. The review highlights the promising data in approval of novel administration routes, likely through inhalation, but further intensive research considering the current obstacles, is essential.
Language:
English
Keywords:
biopharmaceuticals
,
monoclonal antibodies
,
delivery systems
,
patient-friendly therapy
,
subcutaneous administration
Work type:
Article
Typology:
1.01 - Original Scientific Article
Organization:
FFA - Faculty of Pharmacy
Publication status:
Published
Publication version:
Version of Record
Year:
2024
Number of pages:
13 str.
Numbering:
Vol. 667, pt. A, art. 124877
PID:
20.500.12556/RUL-164601
UDC:
615.015.14
ISSN on article:
0378-5173
DOI:
10.1016/j.ijpharm.2024.124877
COBISS.SI-ID:
213575427
Publication date in RUL:
05.11.2024
Views:
57
Downloads:
15
Metadata:
Cite this work
Plain text
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Copy citation
Share:
Record is a part of a journal
Title:
International journal of pharmaceutics
Shortened title:
Int. j. pharm.
Publisher:
Elsevier
ISSN:
0378-5173
COBISS.SI-ID:
3087631
Licences
License:
CC BY 4.0, Creative Commons Attribution 4.0 International
Link:
http://creativecommons.org/licenses/by/4.0/
Description:
This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Secondary language
Language:
Slovenian
Keywords:
biofarmacevtski izdelki
,
monoklonska protitelesa
,
pacientu prijazna terapija
,
subkutana aplikacija
,
dostavni sistemi
Projects
Funder:
ARIS - Slovenian Research and Innovation Agency
Project number:
P1-0189
Name:
Farmacevtska tehnologija: od dostavnih sistemov učinkovin do terapijskih izidov zdravil pri otrocih in starostnikih
Funder:
ARIS - Slovenian Research and Innovation Agency
Project number:
L1-3160
Name:
Razvoj visokokoncentriranih proteinskih formulacij in vrednotenje kinetike absorpcije po subkutani aplikaciji
Similar documents
Similar works from RUL:
Similar works from other Slovenian collections:
Back